Kohima News Paper

Acute Kidney Injury Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, others

 Breaking News
  • No posts were found

Acute Kidney Injury Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, others

May 13
04:02 2021
Acute Kidney Injury Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, others

Acute Kidney Injury Pipeline

Acute Kidney Injury (AKI), also known as acute renal failure (ARF), is a sudden episode of kidney failure or kidney damage. AKI is characterized by abrupt deterioration in kidney function, manifested by an increase in serum creatinine level with or without reduced urine output.

“DelveInsight’s, “Acute Kidney Injury Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Acute Kidney Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Some of Acute Kidney Injury Companies are:

  • Atox Bio
  • AM Pharma Holding
  • Quark-Pharmaceuticals
  • LG Chem
  • Pharming Group
  • Angion Biomedica
  • Elysium Health
  • Sentien Biotechnologies
  • Pharmazz
  • Arch Biopartners
  • Guard Therapeutics
  • RegeneRx Biopharmaceuticals
  • Cerenis Therapeutics
  • And Many Others

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight

 

DelveInsight’s Acute Kidney Injury report covers around 40+ products under different phases of clinical development like:

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of Acute Kidney Injury therapies are:

  • Reltecimod
  • Recombinant alkaline phosphatase
  • Teprasiran
  • Gemigliptin
  • rhC1INH
  • ANG-3777
  • EH 301
  • SBI 101
  • Centhaquine
  • Cilastatin
  • RMC 035
  • Timbetasin RegeneRx Biopharmaceuticals
  • CER 001
  • And Many Others

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight

 

Current Acute Kidney Injury Treatment Scenario and Acute Kidney Injury Emerging Therapies:

  • How many companies are developing Acute Kidney Injury drugs?
  • How many Acute Kidney Injury drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Kidney Injury?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Kidney Injury therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acute Kidney Injury and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight

 

Table of Contents:

Introduction

Executive Summary

Acute Kidney Injury: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Acute Kidney Injury – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

Acute Kidney Injury Collaboration Deals

Late Stage Products (Phase III)

• Comparative Analysis

Teprasiran: Quark-Pharmaceuticals

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

EH 301: Elysium Health

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

• Comparative Analysis

Centhaquine: Pharmazz

Drug profiles in the detailed report…..

Preclinical/Discovery Stage Products

• Comparative Analysis

Timbetasin: RegeneRx Biopharmaceuticals

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Acute Kidney Injury Key Companies

Acute Kidney Injury Key Products

Acute Kidney Injury- Unmet Needs

Acute Kidney Injury- Market Drivers and Barriers

Acute Kidney Injury- Future Perspectives and Conclusion

Acute Kidney Injury Analyst Views

Acute Kidney Injury Key Companies

Appendix

Request for Detailed TOC: https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-pipeline-insight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/acute-kidney-injury-aki-pipeline-insight